2 bold stock market ideas to consider for a Stocks and Shares ISA

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the stock market.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The stock market’s wonderfully diverse, with almost limitless options for a Stocks and Shares ISA. For intrepid investors willing to swing for the fences, here are two high-risk, high-reward ideas to consider.

Gene-editing

First up is biotech firm Crispr Therapeutics (NASDAQ: CRSP) which pioneered the Nobel Prize–winning CRISPR/Cas9 technology to edit genes.

A year ago, it had its first treatment, Casgevy, approved for sickle cell disease and beta-thalassemia, rare blood disorders that are often debilitating for sufferers.

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

Crispr Therapeutics and its partner Vertex Pharmaceuticals have started to collect cells from 50 patients. These will be edited outside the body and reinfused into the patient with the aim of curing them. The NHS is currently rolling out Casgevy.

Looking ahead, the two companies have identified some 58,000 patients in the US, Europe and the Middle East. At a cost of around $2.2m a patient, the revenue opportunity over the next few years could be in the billions (Crispr will get 40% of sales with the rest going to Vertex).

The firm also has a promising gene-editing candidate for blood cancers in the clinic, as well as a potentially revolutionary treatment for type 1 diabetes that aims to restore insulin production.

Naturally, the biotech’s vulnerable to setbacks in these clinical trials. And given the firm’s lack of revenue, never mind profits, the negative impact on the share price would likely be sizeable.

Nevertheless, the company had $1.9bn in cash toward the end of last year, which is enough to fund its exciting pipeline of treatments.

With the share price down 39% over one year, and the firm sporting a modest $1.5bn enterprise value, I think Crispr Therapeutics stock is worth considering.

Created with Highcharts 11.4.3CRISPR Therapeutics PriceZoom1M3M6MYTD1Y5Y10YALL16 Jan 202016 Jan 2025Zoom ▾Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '2520212021202220222023202320242024www.fool.co.uk

Ready for lift-off?

Next up is Archer Aviation (NYSE: ACHR), which is racing to commercialise electric vertical takeoff and landing (eVTOL) aircraft. These take off vertically like helicopters but are near-silent and far greener, making them perfect for congested urban cities (Los Angeles, New York, Tokyo, Abu Dhabi, etc).

Archer intends to launch an Uber-like air taxi service and also sell EV aircraft directly to third-party customers. For example, it recently entered a strategic partnership with Anduril Industries to develop hybrid aircraft for military applications (reconnaissance, for example, given how quiet they are).

Now, the thing here is that the company still hasn’t had its aircraft, called Midnight, fully approved by the Federal Aviation Administration (FAA). It expects to achieve this later in 2025, but there could be regulatory delays (or worse). So this stock’s highly speculative at this stage.

Created with Highcharts 11.4.3Archer Aviation PriceZoom1M3M6MYTD1Y5Y10YALL16 Jan 202016 Jan 2025Zoom ▾Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '2520212021202220222023202320242024www.fool.co.uk

However, there are a few things I like here. First, Archer has nearly completed phase three of the FAA’s four-phase certification process, while making progress through the final stage. And it’s on course to launch a commercial air taxi service in Abu Dhabi later this year.

Next, it has just finished construction of a high-volume, 400,000 sq ft manufacturing facility. With backing from car giant Stellantis, it intends to scale up to 650 aircraft annually by 2030. Archer’s currently well-capitalised and its order book now exceeds $6bn.

Finally, Morgan Stanley estimates the eVTOL market could top $1trn in 15 years! Archer Aviation’s market-cap today is $4.3bn. At $8, I think the stock’s worth considering for adventurous investors.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Uber Technologies. The Motley Fool UK has recommended CRISPR Therapeutics, Uber Technologies, and Vertex Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

artificial intelligence investing algorithms
Investing Articles

Up 272% in just a year, is Palantir stock just getting started?

This writer recognises that Palantir has grown its business very well -- but does the stock price offer him an…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Up 50%? The Aston Martin share price forecast is mind-blowing! 

If analysts are right, the Aston Aston Martin share price could absolutely rocket in the year ahead. Harvey Jones says…

Read more »

Investing Articles

As the S&P 500 drops, here are 2 Stocks and Shares ISA holdings I’m watching

Our writer has different views on how President Trump's tariffs might affect these two US holdings in his Stocks and…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

£10,000 invested in Tesla stock at Christmas is now worth…

Tesla stock has been one of best-performing investments of the past decade. But things haven't gone to plan for investors…

Read more »

Investing Articles

Up 279% in 5 years, could Meta stock keep soaring?

Meta stock has more than tripled in five years. This writer sees lots to like about the business but also…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

25% total return in a year? Is now the perfect time to buy BP shares?

BP shares are on the front line of today's global economic and political uncertainty but analysts think they can still…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

With Cash ISA changes coming, could now be the time to consider buying shares?

Changes to the Cash ISA could lead to greater investment in the stock market. This could be a good thing…

Read more »

Investing Articles

These FTSE 100 dividend shares just got cheaper, thanks to President Trump!

Investors buying dividend shares can lock in bigger long-term yields when share prices take a tumble. These two just did…

Read more »